The MOS for the erlotinib control arm is assumed to be 7 months. So unless they have sicker patients in the trial the alternative has to be bearish if the interim is much earlier than expected.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.